GlassScriptPhysician profile
Julia Y Wen
NPI 1245208982
$42,896.37
in general payments reported to CMS, 2019-2025
65 companies · $4,283 in 2025
The $4,283 reported for 2025 was more than what 91% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,357 · 2020: $6,323 · 2021: $9,219 · 2022: $5,341 · 2023: $4,936 · 2024: $5,437 · 2025: $4,283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,566.11 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,200.54 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $3,804.73 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $3,262.70 | 2019-2025 | Repatha, Evenity, Repatha |
| Viiv Healthcare Company | $3,250.94 | 2019-2025 | Apretude, Dovato, Rukobia |
| Abbvie INC. | $3,107.67 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Janssen Pharmaceuticals, INC | $1,985.33 | 2020-2024 | Xarelto |
| Biohaven Pharmaceuticals, INC. | $1,833.05 | 2021 | |
| Novartis Pharmaceuticals Corporation | $1,621.61 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,585.74 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $1,547.01 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Merck Sharp & Dohme LLC | $1,424.34 | 2019-2025 | Verquvo, Pifeltro, Belsomra |
| Esperion Therapeutics, INC. | $1,289.55 | 2020-2025 | Nexletol |
| Gilead Sciences, INC. | $1,255.17 | 2019-2025 | Sunlenca |
| Pfizer INC. | $1,173.24 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,102.18 | 2019-2025 | Jardiance |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Wen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.